Drug Watch
This detailed page of information is made possible by the hard work and research performed by the Hepatitis B Foundation. Please help us continue to offer this kind of essential resource for the treatment of hepatitis B with a donation toward our important programs. Donate here.
Compounds in Development for Chronic Hepatitis B
Updated May 12, 2023
FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
WEBSITE |
|
|||||||||||||||
| Interferons: Mimic infection-fighting immune substances naturally produced in the body | |||||||||||||||||||
| Intron A (Interferon alfa 2b) | Immunomodulator | Merck, USA | merck.com | Approved 1991 | |||||||||||||||
|
Pegasys (Peginterferon alfa 2a) |
Immunomodulator |
Approved 2005 |
|||||||||||||||||
| Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication | |||||||||||||||||||
|
Epivir (Lamivudine) *Generics available |
Inhibits viral DNA polymerase | GlaxoSmithKline (GSK) | gsk.com | Approved 1998 | |||||||||||||||
| Hepsera (Adefovir dipivoxil) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences, USA | gilead.com | Approved 2002 | |||||||||||||||
|
Baraclude (Entecavir) *Generics available |
Inhibits viral DNA polymerase | Bristol-Myers Squibb, USA | bms.com | Approved 2005 | |||||||||||||||
| Tyzeka (Telbivudine) *Generics available | Inhibits viral DNA polymerase | Novartis, USA | novartis.com | Approved 2006 | |||||||||||||||
| Viread (Tenofovir) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences | gilead.com | Approved 2008 | |||||||||||||||
| Vemlidy (TAF or tenofovir alfenamide) | Prodrug of Tenofovir | Gilead Sciences | gilead.com | Approved 2016 | |||||||||||||||
|
Levovir (Cledvudine) |
Inhibits viral DNA polymerase | Bukwang, S. Korea | bukwang.co.kr | Approved 2006 in S. Korea | |||||||||||||||
|
Direct Acting Antivirals: Targets the virus and interferes in the HBV replication process |
|||||||||||||||||||
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
|||||||||||||||||||
|
VIR-2218 |
RNAi gene silencer |
Phase II |
|||||||||||||||||
|
Xalnesiran (RG6346, |
RNAi gene silencer |
Phase II |
|||||||||||||||||
|
Imdurisan (AB-729) |
RNAi gene silencer |
Phase II | |||||||||||||||||
|
ALG-125755 |
RNAi gene silencer |
Holding for new partner |
|||||||||||||||||
|
BB-103 |
RNAi gene silencer |
benitec.com | Preclinical | ||||||||||||||||
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
|||||||||||||||||||
|
Bulevirtide (Hepcludex) |
Entry inhibitor |
Phase III |
|||||||||||||||||
|
Capsid or Core Inhibitors: Interferes with the viral DNA protein shield |
|||||||||||||||||||
|
ZM-H1505R |
Capsid inhibitor |
Phase II |
|||||||||||||||||
|
EDP-514 |
Capsid inhibitor |
Phase I |
|||||||||||||||||
|
ALG-000184 |
Capsid inhibitor |
Phase I | |||||||||||||||||
|
ABI-H4334 |
Capsid inhibitor |
Phase I | |||||||||||||||||
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
|||||||||||||||||||
|
REP 2139 |
sAg inhibitor |
Phase II |
|||||||||||||||||
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
|||||||||||||||||||
|
Bepirovirsen |
HBV Antisense |
Phase III |
|||||||||||||||||
|
AHB-137 |
HBV Antisense |
AusperBio, China |
Phase I |
||||||||||||||||
|
|||||||||||||||||||
|
Immunologicals: Targets the human immune system to attack the HBV virus |
|||||||||||||||||||
|
Therapeutic Vaccine Technology used to stimulate the immune system as a treatment |
|||||||||||||||||||
|
HeberNasvac |
Therapeutic vaccine |
Studies in Cuba | Phase IV | ||||||||||||||||
|
HepTcell |
Therapeutic vaccine |
Phase II |
|||||||||||||||||
|
VBI-2601 (BRII-179) |
Therapeutic vaccine |
Phase II | |||||||||||||||||
|
VVX001 |
Therapeutic vaccine |
Phase II |
|||||||||||||||||
|
GSK 3528869A |
Therapeutic vaccine |
Phase II | |||||||||||||||||
|
VTP-300 |
Therapeutic vaccine |
Phase II |
|||||||||||||||||
|
CVI-HBV-002 |
Therapeutic vaccine |
Phase I/II |
|||||||||||||||||
|
HB-400 (GS2829/GS6779) |
Therapeutic vaccine |
hookipapharma.com | Phase I | ||||||||||||||||
|
ISA104 |
Therapeutic vaccine |
isa-pharma.com | Phase I | ||||||||||||||||
| CARG-201 | Therapeutic vaccine | CaroGen, USA | carogencorp.com | Preclinical | |||||||||||||||
|
TherVacB |
Therapeutic vaccine |
Preclinical | |||||||||||||||||
|
PRGN-2013 |
Therapeutic vaccine |
precigen.com | Preclinical | ||||||||||||||||
|
VRON-0200 |
Therapeutic vaccine |
viriontx.com | Preclinical | ||||||||||||||||
|
CLB-3000 |
Therapeutic vaccine |
clearbtherapeutics.com | Preclinical | ||||||||||||||||
|
Compounds that activate the innate immune system |
|||||||||||||||||||
|
Selgantolimod (GS9688) |
TLR-8 agonist |
Phase II |
|||||||||||||||||
|
Ruzotolimod (RG7854) |
TLR-7 agonist |
Phase II | |||||||||||||||||
|
CB06 |
TLR-8 agonist |
core-biopharma.com | Phase I | ||||||||||||||||
|
GSK 5251738 |
TLR-8 agonist |
gilead.com | Phase I | ||||||||||||||||
|
YS-HBV-002 |
Activator of TLR3, RIG1, MDA5 |
yishengbio.com | Preclinical | ||||||||||||||||
|
Monoclonal Antibodies: Neutralize or bind the HBV proteins to reduce infection |
|||||||||||||||||||
|
VIR-3434 |
Monoclonal antibody | Vir Biotech, USA | vir.bio | Phase II | |||||||||||||||
| Burfiralimab (IgG4) | Monoclonal antibody | ImmuneMed, South Korea | immunemed.co.kr/eng | Phase II | |||||||||||||||
|
BJT-778 |
Monoclonal antibody | Blue Jay Therapeutics, USA | bluejaytx.com | Phase I | |||||||||||||||
|
RG6449 |
Monoclonal antibody | Roche | roche.com | Phase I | |||||||||||||||
|
Checkpoint Inhibitors: Stimulate exhausted T-cell recognition of HBV-Infected cells |
|||||||||||||||||||
|
ASC22 (KN035 or Envafolimab) |
PDL1 inhibitor | Ascletis Pharma, PR China | ascletis.com | Phase II | |||||||||||||||
|
RG6084 |
PDL1 inhibitor | Roche | roche.com | Phase II | |||||||||||||||
|
AB-101 |
PDL1 inhibitor | Arbutus | arbutusbio.com | FDA hold 4/25/23 | |||||||||||||||
|
Other Immunologicals |
|||||||||||||||||||
|
IMC-I109V |
T-cell Receptor | Immunocore | immunocore.com | Phase I | |||||||||||||||
|
Additional HBV Drugs Under Investigation |
|||||||||||||||||||
|
GSK 4388067A |
Targeted immunotherapy | GSK, USA | gsk.com | Phase II | |||||||||||||||
|
EYP001 |
FXR agonist | Enyo Pharma, France | enyopharma.com | Holding for new partner | |||||||||||||||
|
APG-1387 |
Apoptosis inducer | Ascentage, PR China |
ascentagepharma.com | Phase II | |||||||||||||||
|
GSK 3965193 |
PAPD5/PAPD7 inhibitor |
GSK, USA | gsk.com | Phase I | |||||||||||||||
|
DF-006 |
Small molecule | Drug Farm, Shanghai | drug-farm.com | Phase I | |||||||||||||||
|
AB359 |
CD8 IL-2 immunotherapy | Asher Biotherapeutics, USA | Preclinical | ||||||||||||||||
|
BJT-628 |
Small molecule | Blue Jay Therapeutics, USA | bluejaytx.com | Preclinical | |||||||||||||||
|
Hepatitis Delta Virus (HDV)- A virus that co-infects people already infected with HBV |
|||||||||||||||||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
EU approved 2023 Phase III USA |
|||||||||||||||||
|
Lonafarnib |
Prenylation inhibitor |
Holding for new partner |
|||||||||||||||||
|
REP 2139 |
HBsAg inhibitor |
Phase II |
|||||||||||||||||
|
VIR-2218 + VIR 3434 |
RNAi gene silencer + Monoclonal antibody |
Phase II | |||||||||||||||||
|
BJT-778 |
Monoclonal antibody |
Phase I | |||||||||||||||||
|
AB-543 |
Entry inhibitor |
assemblybio.com | Preclinical | ||||||||||||||||
If you are a person with hepatitis B who is looking for clinical trial or other research opportunities, please visit our patient and provider opportunities page here.